Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Oct 14.

Published in final edited form as: Vaccine. 2009 Feb 13;27(16):2251–2257. doi: 10.1016/j.vaccine.2009.02.024

TABLE 3.

Results from Cohort Model

		Societal Perspective
		Vaccine No Adjuvant		Vaccine with Adjuvant
Adjuvant Cost		Cost	Effectiveness	Cost	Effectiveness
$	0	$76.13 +/− $12.48	0.79 +/− 0.10	$39.26 +/− $5.51	0.81 +/− 0.10
$	10.00	$76.11 +/− $12.58	0.79 +/− 0.10	$49.22 +/− $5.55	0.81 +/− 0.10
$	20.00	$76.13 +/− $12.58	0.78 +/− 0.10	$59.24 +/− $5.50	0.81 +/− 0.10
$	30.00	$77.18 ± $12.66	0.79 +/− 0.10	$69.78 ± $5.62	0.81 +/− 0.10
		Third Party Perspective
		Vaccine No Adjuvant		Vaccine with Adjuvant
Adjuvant Cost		Cost	Effectiveness	Cost	Effectiveness
$	0	$75.77 ± $12.45	0.78 +/− 0.10	$38.47 ± $5.53	0.81 +/− 0.10
$	10.00	$75.57 ± $12.69	0.78 +/− 0.10	$48.35 ± $5.58	0.81 +/− 0.10
$	20.00	$75.90 ± $12.63	0.78 +/− 0.10	$58.45 ± $5.61	0.81 +/− 0.10
$	30.00	$75.93 ± $12.73	0.78 +/− 0.10	$68.51 ± $5.87	0.81 +/− 0.10